TNSN04090A1 - Conjugues de l'hormone de croissance humaine chimiquement modifies - Google Patents

Conjugues de l'hormone de croissance humaine chimiquement modifies

Info

Publication number
TNSN04090A1
TNSN04090A1 TNP2004000090A TNSN04090A TNSN04090A1 TN SN04090 A1 TNSN04090 A1 TN SN04090A1 TN P2004000090 A TNP2004000090 A TN P2004000090A TN SN04090 A TNSN04090 A TN SN04090A TN SN04090 A1 TNSN04090 A1 TN SN04090A1
Authority
TN
Tunisia
Prior art keywords
growth hormone
human growth
chemically modified
modified human
hormone conjugates
Prior art date
Application number
TNP2004000090A
Other languages
English (en)
Inventor
Rory F Finn
Wei Lao
Ned R Siegel
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of TNSN04090A1 publication Critical patent/TNSN04090A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENTION DECRIT UNE HORMONE DE CROISSANCE HUMAINE (hGH) MODIFIEE CHIMIQUEMENT PAR LIAISON DE LA PROTEINE AVEC UN POLYMERE SOLUBLE DANS L'EAU. LA PROTEINE MODIFIEE AU SENS DE L'INVENTION; PRESENTE UNE ACTIVITE hGH QUI DURE BEAUCOUP PLUS LONGTEMPS QUE CELLE DE L'HORMONE NON MODIFIEE; CE QUI PERMET D'EN REDUIRE LA DOSE ET LA FREQUENCE D'ADMINISTRATION.
TNP2004000090A 2001-11-20 2004-05-20 Conjugues de l'hormone de croissance humaine chimiquement modifies TNSN04090A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20
PCT/US2002/037270 WO2003044056A2 (fr) 2001-11-20 2002-11-20 Conjugues de l'hormone de croissance humaine chimiquement modifiee

Publications (1)

Publication Number Publication Date
TNSN04090A1 true TNSN04090A1 (fr) 2006-06-01

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000090A TNSN04090A1 (fr) 2001-11-20 2004-05-20 Conjugues de l'hormone de croissance humaine chimiquement modifies

Country Status (25)

Country Link
EP (1) EP1453859A2 (fr)
JP (2) JP2005525302A (fr)
KR (2) KR20050044858A (fr)
CN (1) CN1608079A (fr)
AP (1) AP2004003050A0 (fr)
AU (1) AU2002356990A1 (fr)
BR (1) BR0214451A (fr)
CA (1) CA2467731A1 (fr)
CO (1) CO5580794A2 (fr)
EA (2) EA200700431A1 (fr)
EC (1) ECSP045114A (fr)
GE (1) GEP20063860B (fr)
HR (1) HRP20040448A2 (fr)
HU (1) HUP0500997A2 (fr)
IL (1) IL162031A0 (fr)
IS (1) IS7268A (fr)
MA (1) MA27544A1 (fr)
MX (1) MXPA04004809A (fr)
NO (1) NO20042182L (fr)
OA (1) OA13063A (fr)
PL (1) PL374354A1 (fr)
RS (1) RS53104A (fr)
TN (1) TNSN04090A1 (fr)
WO (1) WO2003044056A2 (fr)
ZA (1) ZA200403907B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
ME00239B (me) * 2002-01-18 2011-05-10 Biogen Ma Inc Polimerna jedinjenja polialkilena i njihova upotreba
EP1591467A1 (fr) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugue d un polyethylene glycol comprenant un group terminal alcanal et un hormone de croissance humaine
ES2897470T3 (es) 2002-09-09 2022-03-01 Nektar Therapeutics Alcanales poliméricos solubles en agua
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
CN100580087C (zh) * 2003-10-10 2010-01-13 诺和诺德医疗保健公司 肽的缀合
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
EP2368579A1 (fr) * 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Conjugaison au moyen de transglutaminase de peptides
AU2005278903A1 (en) * 2004-08-31 2006-03-09 Pharmacia & Upjohn Company Llc Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
CN103290084A (zh) * 2004-12-22 2013-09-11 Ambrx公司 表达和纯化重组人类生长激素的方法
US7638491B2 (en) 2004-12-22 2009-12-29 Ambrx, Inc. Therapies using non-natural amino acids and polypeptides
CN103690936A (zh) * 2004-12-22 2014-04-02 Ambrx公司 经修饰的人类生长激素
US20090105134A1 (en) 2005-02-10 2009-04-23 Novo Nordisk A/S C-Terminally Pegylated Growth Hormones
EP1877439B1 (fr) 2005-04-18 2011-02-09 Novo Nordisk A/S Variantes de l'il-21
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
AU2006311568B2 (en) 2005-11-08 2010-11-11 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
US20080317670A1 (en) 2005-12-14 2008-12-25 Ambrx, Inc. Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
KR20100014215A (ko) 2006-07-07 2010-02-10 노보 노르디스크 헬스 케어 악티엔게젤샤프트 신규 단백질 접합체 및 그것의 제조 방법
CN101108895B (zh) * 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
JP2010507382A (ja) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ Ｉｌ−２１変異体
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
CA2720306C (fr) 2008-04-03 2016-03-15 Biosteed Gene Expression Tech. Co., Ltd. Hormone de croissance modifiee par polyethyleneglycol double brin, son procede de preparation et son application
KR101104574B1 (ko) * 2008-05-14 2012-01-11 성균관대학교산학협력단 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
KR101533757B1 (ko) * 2008-07-31 2015-07-03 파마이센시아 코퍼레이션 펩티드-중합체 접합체
WO2010015668A1 (fr) 2008-08-06 2010-02-11 Novo Nordisk A/S Protéines conjuguées à efficacité in vivo prolongée
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
JP5766118B2 (ja) * 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法
EP2389389B1 (fr) 2009-01-22 2015-04-15 Novo Nordisk Health Care AG Composés d'hormone de croissance stables
CN105963710A (zh) 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
CN102711733A (zh) 2009-12-15 2012-10-03 阿森迪斯药物股份有限公司 瞬时连接于聚合物载体的干生长激素组合物
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
KR101813595B1 (ko) 2010-01-22 2017-12-29 노보 노르디스크 헬스 케어 악티엔게젤샤프트 장기적 생체 내 효능을 갖는 성장 호르몬
NZ603399A (en) * 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
EP2446898A1 (fr) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Utilisation de l'hormone de croissance pour améliorer la réponse immunitaire chez des patients immunodéprimés
EA019967B1 (ru) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека
EP2981282B1 (fr) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Formulation d'un composé d'hormone de croissance
WO2016073825A1 (fr) 2014-11-06 2016-05-12 Pharmaessentia Corporation Régime posologique pour l'interféron pégylé
ES2896971T3 (es) 2014-11-21 2022-02-28 Ascendis Pharma Endocrinology Div A/S Formas de administración de hormona del crecimiento de acción prolongada
US20190290733A1 (en) * 2015-03-11 2019-09-26 Nektar Therapeutics Conjugates of an il-7 moiety and a polymer
RU2738416C2 (ru) * 2015-09-18 2020-12-14 Юниверсити Оф Миязаки Длительно действующее производное адреномедуллина
CN114539384A (zh) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
ES2113354T3 (es) * 1990-05-04 1998-05-01 American Cyanamid Co Estabilizacion de somatotropinas y otras proteinas por modificacion de residuos de cisteina.
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE69638117D1 (de) * 1995-09-21 2010-03-04 Genentech Inc Varianten des menschlichen Wachstumshormons
WO1999003887A1 (fr) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derives d'hormone de croissance et proteines associees
IL144259A0 (en) * 1999-01-14 2002-05-23 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
ATE246202T1 (de) * 1999-01-29 2003-08-15 Hoffmann La Roche Gcsf konjugate
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
JP2004524020A (ja) * 2001-01-11 2004-08-12 マキシゲン・エイピーエス 改良された成長ホルモン分子

Also Published As

Publication number Publication date
EA200700431A1 (ru) 2008-02-28
HRP20040448A2 (en) 2006-02-28
PL374354A1 (en) 2005-10-17
KR20070072924A (ko) 2007-07-06
CA2467731A1 (fr) 2003-05-30
EA008505B1 (ru) 2007-06-29
BR0214451A (pt) 2006-05-30
MXPA04004809A (es) 2004-08-11
MA27544A1 (fr) 2005-10-03
ZA200403907B (en) 2007-12-27
WO2003044056A2 (fr) 2003-05-30
CN1608079A (zh) 2005-04-20
NO20042182L (no) 2004-08-11
JP2005525302A (ja) 2005-08-25
ECSP045114A (es) 2004-07-23
WO2003044056A3 (fr) 2003-08-21
OA13063A (en) 2006-11-10
GEP20063860B (en) 2006-06-26
KR20050044858A (ko) 2005-05-13
HUP0500997A2 (en) 2007-11-28
CO5580794A2 (es) 2005-11-30
EA200400565A1 (ru) 2005-06-30
AP2004003050A0 (en) 2004-06-30
EP1453859A2 (fr) 2004-09-08
JP2006321808A (ja) 2006-11-30
AU2002356990A1 (en) 2003-06-10
IL162031A0 (en) 2005-11-20
IS7268A (is) 2004-05-17
RS53104A (en) 2006-10-27

Similar Documents

Publication Publication Date Title
TNSN04090A1 (fr) Conjugues de l'hormone de croissance humaine chimiquement modifies
RU2227042C2 (ru) Композиции и способы системной доставки пероральных вакцин и терапевтических агентов
CY1118991T1 (el) Φαρμακοτεχνικη μορφη ανθρωπινων αντισωματων για θεραπεια σχετικων με tnf-αλφα διαταραχων
NO20064676L (no) Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre
DE69010206D1 (de) Stabilisierte protein- oder peptidkonjugate.
EA200300856A1 (ru) Долгоживущие производные рилизинг-фактора гормона роста
EA199900979A1 (ru) Композиции активированного протеина
HUP0004924A2 (hu) Ciklodextrineket tartalmazó gyógyászati készítmények
WO1998051325A3 (fr) Peptides aleatoires se liant au recepteurs de transport du tractus gastrointestinal (git) et procedes y relatifs
EP2270148A3 (fr) Méthode de régulation de l'activité d'une molécule immunologiquement fonctionnelle
ATE410979T1 (de) Vorrichtung zur befestigung und verankerung von herzklappenprothesen
ATE399185T1 (de) Maleinsäureamid polymerderivate und ihre biokonjugate
TNSN95061A1 (fr) Derives d'oxalylamino-benzofuranne et benzothienyle
EE200100507A (et) Hüdroksümatairesinool vähkkasvaja vältimises
BR0316716A (pt) Conjugados quimicamente modificados do hormÈnio do crescimento humano
AU7814498A (en) Multivalent (in ovo) avian vaccine
NO20023464D0 (no) Sammensetning for intestinal avlevering
PT1098643E (pt) Fenilacetilglutamina fenilacetilisoglutamina e/ou fenilacetato para o tratamento de doencas neoplasicas
CA2473068A1 (fr) Derives d'amidon, conjugues amidon-substances actives, procede de production de ces conjugues et leur utilisation comme medicaments
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
DK0981362T3 (da) Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal
WO2000006185A3 (fr) Procedes d'utilisation d'un analogue de somatostatine
DE60218636D1 (de) Antikörper zur vorbeugung und behandlung von e. coli aeec krankheiten
MX9805939A (es) Formas solidas de administracion, de liberacion instantanea y procesos para su produccion.
FR2821359B1 (fr) L'heterocarpine, une proteine fixant le ghrh humain